The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials

Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPis) belong to a class of targeted drugs developed for the treatment of homologous recombination repair (HRR)-defective tumors. Preclinical and limited clinical data suggest that PARP inhibition is effective against prostate cancer (PC) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Mingyue, Guo, Zhigang, Hu, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150298/
https://www.ncbi.nlm.nih.gov/pubmed/34066020
http://dx.doi.org/10.3390/biom11050722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150298/
https://www.ncbi.nlm.nih.gov/pubmed/34066020
http://dx.doi.org/10.3390/biom11050722

Ejemplares similares